https://claude.ai/share/59931ef2-9e4b-4939-a30b-bf1bb5e78d02

Good. I have enough to work with. Let me build this out carefully.

This is a genuinely interesting problem that requires separating the baseline actuarial case from the exotic-scenario adjustments and then weighting them by probability. I'll walk through each layer.

Baseline Actuarial Case

You need to reach January 1, 2100, which is about 74 years from now. That means surviving to age 107.

Male life expectancy at birth in the U.S. was 74.8 years as of 2022. NCBI That's the birth-cohort figure, but you've already survived to 33, which eliminates most of the early-death risk. The relevant number is conditional life expectancy given survival to 33. From SSA period tables, a 33-year-old American male has a remaining expected lifespan of roughly 45-46 additional years, putting the median death around age 78-79. Reaching 107 sits roughly 3.5 standard deviations above the current mean for your cohort (using a rough SD of ~15 years for the lifespan distribution).

In a static-mortality world, surviving to 107 has a probability of well under 1%. The current oldest-verified human ever (Jeanne Calment) died at 122, and the longest verified human lifespan is around 122 years Wikipedia, so 107 is biologically plausible but deeply tail-weighted. A conservative estimate under static mortality: roughly 0.5-1.5%, with the wide uncertainty band coming from the fat tail of the lifespan distribution and the fact that your individual characteristics (unknown to me) shift this considerably.

But static mortality is the wrong frame for this question.

The Secular Trend Adjustment

Mortality rates have been declining for over a century. In the 20th century, life expectancy increased roughly three months for every year lived New Zapiens, a trend that, if it continued linearly, would meaningfully shift the distribution for someone your age. The SSA's own cohort projections (which incorporate expected future mortality improvements, not just current rates) put male life expectancy for your birth cohort several years higher than the period table suggests.

Even under conservative continuation of historical trends with no exotic breakthroughs, the tail probability of reaching 107 improves from the baseline. Call this the "secular drift" scenario: mortality improvements continue at roughly historical rates through 2100. This pushes the probability upward to perhaps 2-4%, reflecting that you'd be dying in a world with substantially better medicine than today, even without any transformative event.

The Exotic Scenarios

Here's where the analysis gets genuinely uncertain, and where you need to reason about scenarios rather than distributions.

Scenario A: Longevity Escape Velocity (LEV) achieved before you age out (~2035-2055)

De Grey predicts a 50% chance humanity reaches longevity escape velocity within the next 12 to 15 years. CEO Today Kurzweil predicts this tipping point could happen by 2029. Biohackingnews George Church answered "I wouldn't be surprised if 2050 would be a point" when asked about reaching LEV. Wikipedia Mainstream gerontologists are much more skeptical. Most mainstream gerontologists raise an eyebrow and say "Come back in the 22nd century — biology is messy." University of Edinburgh

The critical variable for you is not just whether LEV gets achieved, but whether it gets achieved while you're still young enough to benefit. At 33 now, you'll be 50 in 2043 and 67 in 2060. If LEV arrives by 2045, you're 52 and in reasonable shape to benefit. If it arrives in 2075, you might already be in steep decline or dead.

As of early 2026, no trials have yet demonstrated sustained escape velocity-like gains, and regulatory hurdles persist. Grokipedia Mice live longer under certain interventions, but translation to humans has yet to succeed. Funding and research speed are increasing, yet definitive evidence is missing. ASPRIVA

The honest prior on LEV arriving in time for you to benefit (say, by 2055) is somewhere between 5% and 20%, depending on how much weight you put on de Grey-style optimism vs. mainstream gerontology. Call it 10% as a central estimate, with a 2x uncertainty band in either direction.

If LEV arrives, your probability of reaching 2100 goes from a floor of ~1% to something approaching certainty for the non-accident portion of your lifespan. The residual mortality under LEV would come from accidents, violence, and non-aging diseases. Life insurance actuaries studying similar scenarios estimate "background mortality" of roughly 0.3-0.7% per year from non-aging causes under modern conditions, which compounds to a non-trivial probability of death over 74 years even in a world without biological aging. At 0.5% annual background mortality, your probability of surviving 74 accident-free years is about 69%.

So: P(LEV in time) × P(survive to 2100 | LEV) ≈ 0.10 × 0.70 = 7% from this scenario alone.

Scenario B: AI-driven medical acceleration without full LEV

Even without achieving escape velocity, AI may compress drug discovery timelines dramatically. The protein folding problem was intractable for decades until suddenly solved by AlphaFold as one of the very early fruits of current AI progress, and the massive complexity and immense data sets of biology are well suited to being understood. NextBigFuture A scenario where AI adds 10-20 years to your effective lifespan without hitting LEV is plausible and perhaps more likely than full LEV. This would push your effective death distribution out by 1-1.5 standard deviations, more than doubling the tail probability of reaching 107. Probability of this scenario: ~25-35%. Conditional probability of reaching 2100 given this scenario: perhaps 5-10% (you'd still need to be in the right part of the tail). Contribution: roughly 1.5-3%.

Scenario C: Civilizational disruption

The flip side is scenarios that reduce your probability below baseline: great-power war with nuclear exchange, engineered pandemic, climate destabilization severe enough to collapse healthcare infrastructure, or an AI transition that goes poorly. These are not negligible risks over a 74-year horizon. A rough aggregation of catastrophic risk over 74 years from credible sources puts something like a 5-15% chance of civilization-scale disruption bad enough to materially reduce your survival odds. Call the mortality penalty from these scenarios large enough to subtract 1-2% from the total.

Scenario D: Whole-brain emulation or other radical technology

I'll acknowledge this category exists and assign it a small weight (~2-5% probability of relevant deployment in your lifetime), but the conditional probability of "you specifically benefit" under this scenario depends so much on implementation details and your own choices that it's not worth quantifying precisely. Treat it as a small positive tail.

Synthesized Estimate

| Scenario | Weight | P(reach 2100 | scenario) | Contribution | |---|---|---|---| | Static mortality / slow progress | 30% | 1.5% | 0.45% | | Secular trend continuation | 30% | 3.5% | 1.05% | | AI-accelerated medicine (no LEV) | 20% | 7% | 1.40% | | LEV achieved in time | 10% | 70% | 7.00% | | Civilizational disruption | 10% | 0.3% | 0.03% | | Total | | | ~10% |

My central estimate is roughly 10%, with a plausible range of 4-20%. That range is wide because the distribution of futures is genuinely bimodal: either something transformative happens in aging science in the next 20-30 years, or the baseline actuarial case dominates and the probability is under 3%.

Key Sensitivities

The estimate is most sensitive to two variables:

1. Your sex and health: You didn't specify sex with certainty, but I'm treating you as male from context. Women have systematically better survival odds. Individual health behaviors (exercise, not smoking, healthy weight, sleep quality, avoiding accidents) can shift your effective biological age by 5-10 years, which matters a lot in the tail.
2. LEV timing: The single biggest lever is whether longevity research crosses a threshold in the 2035-2055 window. If you assign 20% probability to LEV in time (de Grey's view, roughly), the total estimate climbs to ~17%. If you assign 3% (mainstream gerontology's implied view), it drops to ~5%.
3. Access: Even if rejuvenation therapies arrive, distribution matters. Early treatments will almost certainly be expensive and geographically concentrated. Your probability of benefiting is higher than the global average, but not guaranteed.

Bottom line: I'd put 10% as the honest central estimate, with genuine uncertainty spanning 4% to 20%. The expected value is dominated by the LEV tail rather than the actuarial base case. The single most consequential thing that will determine whether you see the 22nd century is whether aging science gets transformatively better before your 60s, not whether you make it to your 90s by conventional means.

https://claude.ai/share/108e27e3-a29e-4477-83e2-f1c2434c4c5e

This is a genuinely interesting problem because it sits at the intersection of well-understood actuarial science and deeply uncertain technological forecasting. You need to reach approximately age 107 (born ~1993, targeting January 1, 2100). Let me build this up from the baseline and layer in the speculative scenarios.

The Actuarial Baseline

Only 0.4% of US females and 0.09% of US males survive to age 105, and reaching 110 is about 150 times rarer for females and 333 times rarer for males than reaching 100. Boston University Medical Campus These are figures derived from historical cohorts, though, and you'd benefit from being born decades later with better baseline healthcare. For the 1900 birth cohort, 0.51% of males and 3.2% of females lived to 100-104, while only 0.03% of males and 0.25% of females reached 105-109. PubMed Central

For your 1993 birth cohort, period life tables would give you a remaining life expectancy of roughly 44-47 years from age 33, putting the median death age around 77-80 for US males. Reaching 107 is deep into the tail of the distribution. Under a frozen-mortality assumption (no further medical progress at all), the probability for a 33-year-old US male reaching 107 is on the order of 0.1% to 0.3%.

Cohort tables, which account for expected incremental mortality improvements over your lifetime, roughly double or triple that, landing you somewhere around 0.3% to 1% with ordinary medical progress continuing its historical pace of roughly 1.5-2 years of life expectancy gain per decade.

The Scenario Decomposition

Here's where it gets interesting. I'll assign rough probability weights to distinct futures and estimate your conditional survival to 107 in each:

Scenario A: Business as usual (weight: ~35%). Medical progress continues at its incremental historical pace. Cancer survival improves, cardiovascular treatments get better, but no fundamental shift in the biology of aging. Your probability of reaching 107 in this world: roughly 0.5-1.5%.

Scenario B: Meaningful but limited aging interventions (weight: ~30%). Senolytics, rapamycin analogs, GLP-1 combinations, or similar therapies prove to add 5-15 healthy years in humans by the 2040s-2050s. A 2025 study showed rapamycin paired with the MEK inhibitor trametinib extended median mouse lifespan by 27-29%, outperforming single agents through synergistic inhibition of growth signaling. Grokipedia The field in 2025 is shifting from preclinical experiments toward clinical evaluations, with several human longevity trials underway. Healthspan But translating mouse results to humans consistently disappoints, and regulatory hurdles are steep. Your probability of reaching 107 here: roughly 5-15%.

Scenario C: Transformative aging breakthroughs / longevity escape velocity achieved (weight: ~15%). At Radfest 2025, de Grey estimated a 50% chance that by the 2030s we might enter the era of longevity escape velocity, though Kennedy and Kaeberlein were far more cautious, pointing out that animal studies have yet to surpass the known effects of caloric restriction or rapamycin. ASPRIVA In this scenario, partial epigenetic reprogramming, comprehensive damage repair, or some currently unknown intervention achieves genuine biological age reversal in humans by the 2040s-2060s. If this happens while you're in your 50s or 60s, the conditional probability of reaching 107 becomes very high: 50-80%.

Scenario D: AI-accelerated radical transformation (weight: ~10%). Superintelligent or near-superintelligent AI compresses the entire aging-research timeline by orders of magnitude, enabling molecular-level precision medicine and essentially solving aging as an engineering problem. This is the Kurzweil scenario on steroids. If it happens in time for you (say before you're 70), your conditional survival to 107 is 70-90%. But the probability of this scenario materializing on that timeline, and being broadly accessible to someone in your economic position, is itself quite low.

Scenario E: Civilizational disruption (weight: ~10%). Major wars, pandemics, climate-driven collapse, or other catastrophes that reduce life expectancy. Your probability of reaching 107 drops to near zero: ~0.05%.

The Weighted Estimate

Combining these:

P(107) ≈ (0.35 × 0.01) + (0.30 × 0.10) + (0.15 × 0.65) + (0.10 × 0.80) + (0.10 × 0.0005)

P(107) ≈ 0.0035 + 0.030 + 0.0975 + 0.08 + 0.00005

P(107) ≈ 21%

Quantifying the Uncertainty

My point estimate is roughly 15-25%, with a central value around 20%. But the confidence interval is enormously wide because the variance is dominated by the binary question of whether transformative aging interventions arrive in time.

If I had to give a 90% credible interval: 3% to 45%.

The distribution is heavily right-skewed and bimodal in an important sense. In most futures where aging research doesn't pan out, you almost certainly die before 107. In the minority of futures where it does, you probably cruise past 107 comfortably. There's relatively little probability mass in the "just barely made it" zone.

Key Sensitivities

The factors that most move the needle for you specifically:

Your current health and genetics are the single largest individual-level variable. The estimate above assumes roughly average health for a 33-year-old American male. If you have strong family longevity, no chronic conditions, healthy weight, and regular exercise, shift the baseline scenarios upward meaningfully. If you have significant risk factors, shift them down.

When breakthroughs arrive matters enormously. A transformative therapy available in 2045 (when you're 52) is worth far more to you than one available in 2075 (when you're 82 and may already have accumulated irreversible damage). The value function is steeply convex with respect to timing.

Access and distribution is underrated as a variable. Early longevity therapies will likely be expensive and unevenly distributed. Your economic trajectory over the next 30-40 years determines whether you're in the first wave or the fifth wave of adoption.

The catastrophe risk is real and probably underweighted in most longevity-optimist analyses. A 74-year horizon is long enough for multiple potential civilizational disruptions, and those scenarios are strongly correlated with each other in ways that compress the tail.

The honest bottom line: you're probably in the range of a 1-in-5 to 1-in-6 shot, with the vast majority of the probability mass coming from speculative technological scenarios rather than actuarial extrapolation. The base rate is brutal. The optionality from being 33 right now, during what might be the critical window for aging research, is what makes it a real question and not a flat "no."